Blog
RSS FeedPosted by Michael Wonder on 18 Jul 2019
Canada warns U.S. against drug import plans, citing shortage concerns
18 July 2019 - Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country’s drug supply ...
Posted by Michael Wonder on 17 Jul 2019
Majority of patients not asked for consent before being switched to a biosimilar, survey finds
17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...
Posted by Michael Wonder on 17 Jul 2019
On drug prices, Trump must resist left-wing approaches that would lead to disaster
17 July 2019 - In Friday's column, I explained why President Donald Trump and the Republicans are on their way ...
Posted by Michael Wonder on 17 Jul 2019
Car shopping, handbags and wealthy uncles: the quest to explain high drug prices
17 July 2019 - High drug prices are a hot topic in politics right now. President Trump has made lowering ...
Posted by Michael Wonder on 17 Jul 2019
Durect announces that the FDA agreed to file the full response to the Posimir complete response letter as a complete Class 2 resubmission
17 July 2019 - User fee goal date is 27 December 2019. ...
Posted by Michael Wonder on 17 Jul 2019
Perth boy battles cystic fibrosis, with a life extending drug frustratingly out of reach
15 July 2019 - In many ways Connor Barrett is just like any other kid - he loves Peppa Pig ...
Posted by Michael Wonder on 17 Jul 2019
Early payouts for health care super silly, Treasury told
18 July 2019 - The superannuation sector has warned Treasury that letting people use retirement savings to pay for private ...
Posted by Michael Wonder on 17 Jul 2019
Trump to order drive for improved flu vaccine
16 July 2019 - President Donald Trump is readying an executive order that would direct HHS to overhaul the development ...
Posted by Michael Wonder on 17 Jul 2019
U.S. FDA accepts Allergan's new drug application for bimatoprost sustained release in patients with open-angle glaucoma or ocular hypertension
17 July 2019 - Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained ...
Posted by Michael Wonder on 17 Jul 2019
FDA approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of adults with complicated urinary tract and complicated intra-abdominal bacterial infections where limited or no alternative treatment options are available
17 July 2019 - Merck today announced that the U.S. FDA has approved Recarbrio (imipenem, cilastatin, and relebactam) for injection, 1.25 ...
Posted by Michael Wonder on 17 Jul 2019
Kamala Harris introduces plan to lower prescription drug prices
16 July 2019 - Senator Kamala Harris unveiled a plan Tuesday to lower prescription drug prices if she's elected president. ...
Posted by Michael Wonder on 17 Jul 2019
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 17 Jul 2019
Drug Utilisation Sub-Committee outcome statement
17 July 2019 - The outcome statement from the June 2019 Drug Utilisation Sub-Committee meeting is now available. ...
Posted by Michael Wonder on 17 Jul 2019
LogicBio Therapeutics receives rare paediatric disease designation for LB-001 for the treatment of methylmalonic acidaemia
16 July 2019 - LogicBio Therapeutics today announced the U.S. FDA has granted rare paediatric disease designation to LB-001, a ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
Posted by Michael Wonder on 16 Jul 2019
How pharma, under attack from all sides, keeps winning in Washington
16 July 2019 - It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy ...